<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01615874</url>
  </required_header>
  <id_info>
    <org_study_id>P05574</org_study_id>
    <secondary_id>2009-010108-27</secondary_id>
    <nct_id>NCT01615874</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)</brief_title>
  <official_title>A Six-week Evaluator-Blind, Randomized, Active-Controlled Evaluation of the Effects of Three Doses of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI), Montelukast, and Beclomethasone Dipropionate (BDP HFA) on the HPA Axis in Asthmatic Children 5 to 11 Years of Age (Protocol No. P05574/PN158)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of one of five possible study medications
      used in the treatment of asthma on blood plasma cortisol levels in children aged 5-11 years
      with persistent asthma.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Plasma Cortisol Area Under the Curve (AUC) 0-24 hrs</measure>
    <time_frame>Baseline (Day 1) and Day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Plasma Cortisol Trough Concentration (Ctrough)</measure>
    <time_frame>Baseline (Day 1) and Day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>MF/F MDI 50/10 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MF/F MDI 100/10 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MF/F MDI 200/10 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BDP HFA 160 mcg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast 5 mg QD (4 mg QD for 5-year-olds)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MF/F Metered Dose Inhaler (MDI) 25/5 mcg</intervention_name>
    <description>MF/F MDI 25/5 mcg, 2 inhalations twice a day (BID)</description>
    <arm_group_label>MF/F MDI 50/10 mcg BID</arm_group_label>
    <other_name>SCH 418131</other_name>
    <other_name>MK-0887A</other_name>
    <other_name>DULERA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MF/F MDI 50/5 mcg</intervention_name>
    <description>MF/F MDI 50/5 mcg, 2 inhalations BID</description>
    <arm_group_label>MF/F MDI 100/10 mcg BID</arm_group_label>
    <other_name>SCH 418131</other_name>
    <other_name>MK-0887A</other_name>
    <other_name>DULERA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MF/F MDI 100/5 mcg</intervention_name>
    <description>MF/F MDI 100/5 mcg, 2 inhalations BID</description>
    <arm_group_label>MF/F MDI 200/10 mcg BID</arm_group_label>
    <other_name>SCH 418131</other_name>
    <other_name>MK-0887A</other_name>
    <other_name>DULERA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDP hydrofluoroalkane (HFA) 80 mcg</intervention_name>
    <description>BDP HFA 80 mcg, 2 inhalations BID</description>
    <arm_group_label>BDP HFA 160 mcg BID</arm_group_label>
    <other_name>BECONASE AQ®</other_name>
    <other_name>QVAR®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast tablets 5 mg (4 mg for children 5 years of age)</intervention_name>
    <description>Montelukast chewable tablets 5 mg once daily (QD) for children 6-11 years of age
OR
Montelukast chewable tablets 4 mg QD for children 5 years of age</description>
    <arm_group_label>Montelukast 5 mg QD (4 mg QD for 5-year-olds)</arm_group_label>
    <other_name>MK-0476</other_name>
    <other_name>SINGULAIR®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rescue medication: short-acting beta-2 agonist (SABA) MDI</intervention_name>
    <description>albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed</description>
    <arm_group_label>MF/F MDI 50/10 mcg BID</arm_group_label>
    <arm_group_label>MF/F MDI 100/10 mcg BID</arm_group_label>
    <arm_group_label>MF/F MDI 200/10 mcg BID</arm_group_label>
    <arm_group_label>BDP HFA 160 mcg BID</arm_group_label>
    <arm_group_label>Montelukast 5 mg QD (4 mg QD for 5-year-olds)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rescue medication: Prednisone/Prednisolone</intervention_name>
    <description>Prednisone/Prednisolone for rescue medication, taken as directed</description>
    <arm_group_label>MF/F MDI 50/10 mcg BID</arm_group_label>
    <arm_group_label>MF/F MDI 100/10 mcg BID</arm_group_label>
    <arm_group_label>MF/F MDI 200/10 mcg BID</arm_group_label>
    <arm_group_label>BDP HFA 160 mcg BID</arm_group_label>
    <arm_group_label>Montelukast 5 mg QD (4 mg QD for 5-year-olds)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of persistent asthma of ≥6 months duration

          -  body weight ≥18 kg

          -  able to discontinue prescribed inhaled corticosteroid (ICS) or ICS combined with
             long-acting beta-agonist (LABA) before starting study medication

          -  use of a low or medium daily dose of ICS (either alone or in combination with a LABA)
             with no use of oral corticosteroids within 3 months prior to Screening Visit

          -  stable asthma regimen (daily dose unchanged) for ≥2 weeks prior to Screening Visit

          -  documented positive responsiveness to bronchodilators

          -  ability to use a peak flow meter correctly and to perform spirometry and PEF
             measurements

          -  ability to use an inhaler correctly

          -  consent/assent for the trial and for pharmacogenetic testing (Note: If unwilling to
             consent/assent for pharmacogenetic testing, inclusion in the study is still allowed,
             but no pharmacogenetic samples will be obtained.)

        Exclusion Criteria:

          -  use of a high dose of ICS for ≥30 days within 6 months prior to Screening Visit

          -  treatment in the emergency room (for a severe asthma exacerbation requiring systemic
             corticosteroid treatment) or hospitalization for management of airway obstruction
             within 3 months prior to Screening Visit

          -  ever required ventilator support for respiratory failure secondary to asthma

          -  upper or lower respiratory tract infection (viral or bacterial) within 2 weeks prior
             to Screening Visit

          -  clinically significant abnormal vital sign

          -  evidence of oropharyngeal candidiasis

          -  history of clinically significant renal, hepatic, cardiovascular, metabolic,
             neurologic, hematologic, ophthalmologic, respiratory, gastrointestinal,
             cerebrovascular, or other significant medical illness or disorder that may interfere
             with study participation. Specific examples include but are not limited to
             insulin-dependent diabetes, active hepatitis, cardiovascular disease including
             hypertension, or conditions that may interfere with respiratory function such as,
             bronchiectasis, and cystic fibrosis

          -  allergy to or intolerance of corticoids, beta-2 agonists, montelukast or any of the
             inactive ingredients in the medications used in this study

          -  participation in this same study at another study site

          -  previous randomization into this study

          -  participation in another investigational study for the duration of this study

          -  use of any investigational drug within one month prior to Screening Visit

          -  previous participation in a study with MF/F or montelukast

          -  direct association with or family member of one of the investigators or study staff

          -  sibling of a participant in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2012</study_first_submitted>
  <study_first_submitted_qc>June 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2012</study_first_posted>
  <last_update_submitted>September 25, 2015</last_update_submitted>
  <last_update_submitted_qc>September 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Mometasone Furoate, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

